EZH2 protein: A promising immunomarker for the detection of hepatocellular carcinomas in liver needle biopsies

Gut

Volumn 60, Issue 7, 2011, Pages 967-976

  Cai, Mu Yan ^a,b   Tong, Zhu Ting ^a   Zheng, Fang ^a   Liao, Yi Ji ^a   Wang, Yi ^a   Rao, Hui Lan ^a,b   Chen, Yang Chao ^c   Wu, Qiu Liang ^a,b   Liu, Yan Hui ^d   Guan, Xin Yuan ^a   Lin, Marie C ^a,c   Zeng, Yi Xin ^a   Kung, Hsiang Fu ^a,c   Xie, Dan ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b SUN YAT SEN UNIVERSITY   (China)

^c CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^d GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; GLYPICAN 3; HEAT SHOCK PROTEIN 70; TRANSCRIPTION FACTOR EZH2;

ADULT; AGED; ARTICLE; CANCER STAGING; CELL LEVEL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; EARLY DIAGNOSIS; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER FOCAL NODULAR HYPERPLASIA; LIVER NODULE; MAJOR CLINICAL STUDY; MALE; MOLECULAR DYNAMICS; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; SENSITIVITY AND SPECIFICITY;

ADULT; BIOPSY; CARCINOMA, HEPATOCELLULAR; CELL DIFFERENTIATION; DNA-BINDING PROTEINS; EPIDEMIOLOGIC METHODS; FEMALE; GLYPICANS; HSP70 HEAT-SHOCK PROTEINS; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASM STAGING; PROGNOSIS; TRANSCRIPTION FACTORS; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 79958219307     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gut.2010.231993     Document Type: Article

References (33)

1. Ince N, Wands JR. The increasing incidence of hepatocellular carcinoma. N Engl J Med 1999;340:798-9. (Pubitemid 29114300)
2. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999;340:745-50. (Pubitemid 29114292)
3. Hsu YC, Fu HH, Jeng YM, et al. Proline-directed protein kinase FA is a powerful and independent prognostic predictor for progression and patient survival of hepatocellular carcinoma. J Clin Oncol 2006;24:3780-8.
4. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005;42:1208-36. (Pubitemid 43112690)
5. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003;362:1907-17. (Pubitemid 37518510)
6. Nomura F, Ishijima M, Kuwa K, et al. Serum des-gamma-carboxy prothrombin levels determined by a new generation of sensitive immunoassays in patients with small-sized hepatocellular carcinoma. Am J Gastroenterol 1999;94:650-4. (Pubitemid 29124861)
7. Chen ZM, Crone KG, Watson MA, et al. Identification of a unique gene expression signature that differentiates hepatocellular adenoma from well-differentiated hepatocellular carcinoma. Am J Surg Pathol 2005;29:1600-8.
8. Wee A. Diagnostic utility of immunohistochemistry in hepatocellular carcinoma, its variants and their mimics. Appl Immunohistochem Mol Morphol 2006;14:266-72. (Pubitemid 44319051)
9. Marrero JA. Modern diagnosis of hepatocellular carcinoma: utilization of liver biopsy and genomic markers. J Hepatol 2009;50:659-61.
10. Cao R, Wang L, Wang H, et al. Role of histone H3 lysine 27 methylation in polycombgroup silencing. Science 2002;298:1039-43. (Pubitemid 35247314)
11. Simon JA, Lange CA. Roles of the EZH2 histone methyltransferase in cancer epigenetics. Mutat Res 2008;647:21-9.
12. Varambally S, Dhanasekaran SM, Zhou M, et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 2002;419:624-9.
13. Chen Y, Lin MC, Yao H, et al. Lentivirus-mediated RNA interference targeting enhancer of zeste homolog 2 inhibits hepatocellular carcinoma growth through downregulation of stathmin. Hepatology 2007;46:200-8. (Pubitemid 47171937)
14. Sudo T, Utsunomiya T, Mimori K, et al. Clinicopathological significance of EZH2 mRNA expression in patients with hepatocellular carcinoma. Br J Cancer 2005;92:1754-8. (Pubitemid 40756488)
15. Yonemitsu Y, Imazeki F, Chiba T, et al. Distinct expression of polycomb group proteins EZH2 and BMI1 in hepatocellular carcinoma. Hum Pathol 2009;40:1304-11.
16. Sasaki M, Ikeda H, Itatsu K, et al. The overexpression of polycomb group proteins Bmi1 and EZH2 is associated with the progression and aggressive biological behavior of hepatocellular carcinoma. Lab Invest 2008;88:873-82.
17. Capurro M, Wanless IR, Sherman M, et al. Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma. Gastroenterology 2003;125:89-97. (Pubitemid 36799110)
18. Yamauchi N, Watanabe A, Hishinuma M, et al. The glypican 3 oncofetal protein is a promising diagnostic marker for hepatocellular carcinoma. Mod Pathol 2005;18:1591-8. (Pubitemid 41670658)
19. Llovet JM, Chen Y, Wurmbach E, et al. A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis. Gastroenterology 2006;131:1758-67. (Pubitemid 46001394)
20. Chuma M, Sakamoto M, Yamazaki K, et al. Expression profiling in multistage hepatocarcinogenesis: identification of HSP70 as a molecular marker of early hepatocellular carcinoma. Hepatology 2003;37:198-207. (Pubitemid 36042161)
21. Di Tommaso L, Franchi G, Park YN, et al. Diagnostic value of HSP70, glypican 3, and glutamine synthetase in hepatocellular nodules in cirrhosis. Hepatology 2007;45:725-34. (Pubitemid 46450624)
22. Di Tommaso L, Destro A, Seok JY, et al. The application of markers (HSP70, GPC3 and GS) in liver biopsies is useful for detection of hepatocellular carcinoma. J Hepatol 2009;50:746-54.
23. Terminology of nodular hepatocellular lesions. International Working Party. Hepatology 1995;22:983-93.
24. Sobin LH, Fleming ID. TNM Classification of Malignant Tumors, fifth edition (1997). Union Internationale Contre le Cancer and the American Joint Committee on Cancer. Cancer 1997;80:1803-4.
25. Xie D, Sham JS, Zeng WF, et al. Heterogeneous expression and association of beta-catenin, p16 and c-myc in multistage colorectal tumorigenesis and progression detected by tissue microarray. Int J Cancer 2003;107:896-902. (Pubitemid 37429830)
26. Cai MY, Zhang B, He WP, et al. Decreased expression of PinX1 protein is correlated with tumor development and is a new independent poor prognostic factor in ovarian carcinoma. Cancer Sci 2010;101:1543-9.
27. Seimiya M, Tomonaga T, Matsushita K, et al. Identification of novel immunohistochemical tumor markers for primary hepatocellular carcinoma; clathrin heavy chain and formiminotransferase cyclodeaminase. Hepatology 2008;48:519-30.
28. Forner A, Vilana R, Ayuso C, et al. Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma. Hepatology 2008;47:97-104. (Pubitemid 351171046)
29. Forner A, Bruix J. Locoregional treatment for hepatocellular carcinoma: from clinical exploration to robust clinical data, changing standards of care. Hepatology 2008;47:5-7. (Pubitemid 351171033)
30. Kojiro M, Roskams T. Early hepatocellular carcinoma and dysplastic nodules. Semin Liver Dis 2005;25:133-42. (Pubitemid 40781066)
31. Roncalli M. Hepatocellular nodules in cirrhosis: focus on diagnostic criteria on liver biopsy. A Western experience. Liver Transpl 2004;10:S9-15.
32. Roncalli M, Borzio M, Di Tommaso L. Hepatocellular dysplastic nodules. Hepatol Res 2007;37(Suppl 2):S125-34.
33. Hytiroglou P, Park YN, Krinsky G, et al. Hepatic precancerous lesions and small hepatocellular carcinoma. Gastroenterol Clin North Am 2007;36:867-87, vii.